Halozyme TherapeuticsHALO
Recorded

Halozyme Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration56 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please note, this event is being recorded. I will now turn the call over to Tram Bui, Halozyme's Vice President of Investor Relations.

Tram BuiVP of Investor Relations

Please go ahead. Thank you, operator.

Tram BuiVP of Investor Relations

Good afternoon, and welcome to Halozyme's third quarter 2026 financial and operating results conference call. In addition to the press release issued today after the market close, you can find a supplementary slide presentation that will be referenced during today's call in the investor relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business, and Darren Snellgrove, our Chief Financial Officer, who will review our financial results and outlook. On today's call, we will be making forward-looking statements as outlined on slide two. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed.

Tram BuiVP of Investor Relations

Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation. I will now turn the call over to Dr. Helen Torley, and we will start on slide three.

Helen TorleyPresident and CEO

Thank you, Tram, and good afternoon, everyone. I am pleased to report another exceptionally strong quarter for Halozyme, as more patients, physicians, and healthcare systems experience the benefits of subcutaneous delivery with ENHANZE. This is reflected in the record total and royalty revenues. Operationally, we continue to demonstrate new growth opportunities resulting from our compounding platform engine, ENHANZE. In and post the quarter, we significantly expanded the ENHANZE opportunity, with three current partners expanding their agreements to add four new target nominations. Additionally, three ENHANZE-enabled programs, one each from Pfizer, Incyte, and argenx, advanced into phase I development. GSK plans to initiate a phase I-B study of a subcutaneous formulation of belantamab with ENHANZE. With this planned start, we are on track to achieve 13 ENHANZE programs in clinical development by year-end.

Helen TorleyPresident and CEO

Importantly, we also advanced our two hyperconcentration technologies, Hypercon and Aerocon, the new name for Surf Bio, moving these closer to clinical testing. All of this contributed to the record total revenue, royalty revenue, and adjusted EBITDA for Q3. Total revenue increased 39% year-over-year to $493 million, driven by royalty revenue, which increased 44% to a record $341 million. These results reflect the continued growth of our established commercial partner product portfolio and the growing contributions from the newer launches, which is resulting in a diversified and growing set of royalty revenue streams. Profitability remained strong during the quarter, with adjusted EBITDA of $336 million and an adjusted EBITDA margin of 68%, reflecting our disciplined execution. Based on this strength, we are raising our full-year 2026 financial guidance. Darren will be discussing this in greater detail.

Helen TorleyPresident and CEO

Turning to slide four, let me now say a few more words about how we are increasing the ENHANZE opportunity through expanded agreements and new nominations by current partners. Three current ENHANZE partners expanded their collaborations and nominated four additional targets. argenx expanded their agreement to include two additional exclusive targets, bringing the total to eight. Incyte expanded and added one additional target to evaluate subcutaneous axatilimab. In October, Johnson & Johnson added an additional oncology target to its longstanding ENHANZE collaboration. Collectively, these four new nominations expand the opportunity, further diversify our partnered pipeline, and add new potential sources of milestone and royalty revenue. Let me now move to slide five, and I'll provide some performance highlights on our commercial ENHANZE portfolio. DARZALEX subcutaneous, VYVGART Hytrulo, and PHESGO have all continued to demonstrate strong royalty revenue growth.

Helen TorleyPresident and CEO

In addition to and on top of this, OCREVUS ZUNOVO, OPDIVO Qvantig, and RYBREVANT FASPRO are adding increasingly meaningful royalty revenues. ENHANZE provides a competitive advantage for our partners by improving convenience, reducing administration time, and in some cases, improving the safety and tolerability profile compared to the IV treatment. For multiple partner products, these benefits are resulting in strong growth as the SC enables new sites of care and increase access to and for patients. I'll begin with highlights on the newer launch products. Roche continues to report strong momentum for subcutaneous OCREVUS ZUNOVO, with approximately 56,000 patients globally now receiving the 10-minute subcutaneous formulation, an increase of about 12,000 patients since the first half of the year. Global conversion from OCREVUS IV to subcutaneous has now exceeded 20%, with adoption driven by both conversion and, importantly, new patients starting on OCREVUS ZUNOVO.

Helen TorleyPresident and CEO

Roche noted on their third quarter call that approximately 50% of the OCREVUS ZUNOVO starts are patients naive to OCREVUS treatment. This, I believe, demonstrates expansion of OCREVUS ZUNOVO into community and more rural treatment settings where IV capacity can be limited. Roche continues to expect high single-digit OCREVUS growth in 2026 and 9 billion Swiss francs, or approximately $11 billion, in peak franchise sales by 2029. At just over 20% conversion to date, and with royalty revenues to at least 2034, this represents a large opportunity for Halozyme. I'll move now to Bristol Myers Squibb and OPDIVO Qvantig. On its third quarter call, BMS reported that approximately 17% of the OPDIVO IV business has already converted to OPDIVO Qvantig, which is the subcutaneous formulation, with uptake occurring across multiple tumor types.

Helen TorleyPresident and CEO

Importantly, they also commented that conversion is tracking towards the higher end of its expectation for 30%-40% of the IV business to ultimately convert to the subcutaneous formulation. SC administration with ENHANZE is delivering meaningful benefits for patients and physicians, including improved practice efficiency and a more convenient treatment experience. With durable royalties projected for many years and significant conversion ahead, this also represents an attractive growth royalty stream. Johnson & Johnson's RYBREVANT FASPRO is another exciting opportunity. J&J reported 63.5% growth of RYBREVANT plus LAZCLUZE in the third quarter, driven by strong share gains in both first and second-line lung cancer treatment, continued launch uptake across regions, and rapid adoption of the subcutaneous version, RYBREVANT FASPRO.

Helen TorleyPresident and CEO

They further noted that they expect FDA approval of RYBREVANT FASPRO in advanced head and neck cancer by the end of 2026, which would expand the opportunity beyond lung cancer into another area of significant unmet need. Johnson & Johnson also highlighted that RYBREVANT is one of their key newer products that is expected to contribute more meaningfully to future growth, and have commented that this growth will be fueled by RYBREVANT FASPRO. This represents another growth royalty revenue stream for Halozyme, with royalty revenues projected to the late 2030s. I'll now move to DARZALEX subcutaneous, VYVGART Hytrulo, and PHESGO. I'll begin with DARZALEX. J&J reported $4.2 billion in sales in the third quarter for DARZALEX, reflecting operational growth of 15.6%. Virtually all of the DARZALEX reported sales are for the DARZALEX subcutaneous version with ENHANZE.

Helen TorleyPresident and CEO

This strong performance was driven by continued share gains across all lines of therapy, including 10 points of share gain in the frontline setting, together with ongoing market expansion. With analysts now projecting sales of $21 billion in 2028, we are excited to support the continued growth and expansion of this exceptional product. I'll move now to VYVGART Hytrulo. argenx reported total VYVGART sales of $1.7 billion in the quarter, impressive growth of 54% year-over-year and 13% sequentially. argenx highlighted continued growth in both generalized myasthenia gravis and CIDP, which is driven by the VYVGART Hytrulo prefilled syringe that provides greater patient convenience and flexibility in how treatment is administered. A recent additional driver of growth is the approval for seronegative myasthenia gravis, which is already broadening their prescriber base, with approximately 10% of seronegative prescribers new to VYVGART.

Helen TorleyPresident and CEO

Further opportunity expansion is projected in 2027, with potential approvals in ocular and pediatric myasthenia gravis. Beyond myasthenia gravis and CIDP, argenx is seeking to expand into a new population of patients, those with immune-mediated necrotizing myositis, or IMNM, with a sBLA planned by year-end. This is a high unmet need patient population, where argenx has estimated there are approximately 20,000 patients living with this disease in the United States alone. These opportunities reinforce the potential for VYVGART Hytrulo to continue expanding across indications, patient populations, and prescribers, delivering long-term growth and projected royalty revenues to Halozyme into the 2040s. Moving now to Roche's PHESGO. In the third quarter, Roche reported that PHESGO also continued to deliver strong performance, with global conversion reaching 59%, up 5 percentage points since mid-year, signaling continued strong adoption for a product that was launched six years ago in 2020.

Helen TorleyPresident and CEO

The continued conversion from PERJETA reinforces the durability of PHESGO, with royalties projected into the 2030s, and the value of ENHANZE in enabling sustained adoption of subcutaneous therapies. Collectively, all six products are demonstrating the continued scalability and durability of ENHANZE. Our established products continue to deliver strong growth, our newer launches are becoming increasingly meaningful contributors, and the ongoing clinical, regulatory, and commercial progress are providing multiple drivers for future revenue growth. Moving now to slide six. With the new study starts in the third quarter, we have significantly expanded our product development pipeline. To date, we have 12 ENHANZE programs in clinical development, three of which the partners have requested to keep confidential at this time. With GSK planning to initiate a phase I-B study of a subcutaneous formulation of belantamab with ENHANZE, we are on track to reach 13 clinical stage programs by year-end 2026.

Helen TorleyPresident and CEO

Recent advancements to highlight are Pfizer's initiation of a phase I study of tilrekimig, their investigational potential first-in-class trispecific antibody that simultaneously inhibits upstream and downstream drivers of type 2 inflammation. Also, Incyte's initiation of a phase I study evaluating a subcutaneous formulation of their first-in-class antibody designed to selectively target mutant calreticulin. Finally, argenx's evaluation of ARGX-119, their first-in-class humanized agonist monoclonal antibody targeting MuSK. Importantly, multiple partners are moving programs from collaboration signing into the clinic rapidly within months of signing. This momentum is a strong reflection of a broader trend in biopharmaceutical companies focusing on subcutaneous administration. Subcutaneous delivery is now recognized not simply as a convenience feature, but as an important driver of patient preference, healthcare system efficiency, competitive differentiation, and market expansion.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day